TY - JOUR
T1 - Addiction-like manifestations and Parkinson's disease
T2 - A large single center 9-year experience
AU - Limotai, Natlada
AU - Oyama, Genko
AU - Go, Criscely
AU - Bernal, Oscar
AU - Ong, Tiara
AU - Moum, Sarah J.
AU - Bhidayasiri, Roongroj
AU - Foote, Kelly D.
AU - Bowers, Dawn
AU - Ward, Herbert
AU - Okun, Michael S.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/3
Y1 - 2012/3
N2 - Objective: Characterize potential risk factors and the relationship of dopamine agonist (DA) withdrawal syndrome (DAWS), dopamine dysregulation syndrome (DDS), and impulse control disorders (ICDs) in Parkinson's disease (PD). Methods: A retrospective chart review categorized cases into three groups: DAWS, DDS, and ICDs. Results: A total of 1,040 subjects met inclusion criteria. There were 332 subjects with a history of tapering DAs and 26 (7.8%) developed DAWS. Fourteen (1.3%) and 89 (8.6%) met the criteria for both DDS and ICD. Subjects with DAWS, DDS, and ICDs had a higher baseline dose of DA, levodopa, and total dopaminergic medication (p < .05), compared to those without the three conditions. DDS was found to be related to the DAWS group (p < .001). When comparing to the PD population without DDS, younger age at onset of PD (p = .027), presence of DAWS (p < .001), ICDs (p = .003), and punding (p = .042) were all correlated with the DDS group, while male sex (p = .045), younger age at onset of PD (p < .001), presence of DAWS (p < .001), and presence of DDS (p = .001) and punding (p < .001) were related to the ICD group. Conclusions: There was a strong relationship between DAWS, DDS, and ICD in this large PD cohort. Dopaminergic therapy in a subset of PD patients was strongly associated with addiction-like behavioral issues.
AB - Objective: Characterize potential risk factors and the relationship of dopamine agonist (DA) withdrawal syndrome (DAWS), dopamine dysregulation syndrome (DDS), and impulse control disorders (ICDs) in Parkinson's disease (PD). Methods: A retrospective chart review categorized cases into three groups: DAWS, DDS, and ICDs. Results: A total of 1,040 subjects met inclusion criteria. There were 332 subjects with a history of tapering DAs and 26 (7.8%) developed DAWS. Fourteen (1.3%) and 89 (8.6%) met the criteria for both DDS and ICD. Subjects with DAWS, DDS, and ICDs had a higher baseline dose of DA, levodopa, and total dopaminergic medication (p < .05), compared to those without the three conditions. DDS was found to be related to the DAWS group (p < .001). When comparing to the PD population without DDS, younger age at onset of PD (p = .027), presence of DAWS (p < .001), ICDs (p = .003), and punding (p = .042) were all correlated with the DDS group, while male sex (p = .045), younger age at onset of PD (p < .001), presence of DAWS (p < .001), and presence of DDS (p = .001) and punding (p < .001) were related to the ICD group. Conclusions: There was a strong relationship between DAWS, DDS, and ICD in this large PD cohort. Dopaminergic therapy in a subset of PD patients was strongly associated with addiction-like behavioral issues.
KW - agonist
KW - complications
KW - deep brain stimulation
KW - dopamine
KW - levodopa
KW - reward
UR - http://www.scopus.com/inward/record.url?scp=84856870571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856870571&partnerID=8YFLogxK
U2 - 10.3109/00207454.2011.633722
DO - 10.3109/00207454.2011.633722
M3 - Review article
C2 - 22023411
AN - SCOPUS:84856870571
SN - 0020-7454
VL - 122
SP - 145
EP - 153
JO - International Journal of Neuroscience
JF - International Journal of Neuroscience
IS - 3
ER -